These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 579512)

  • 21. The interactions of fibrinogen and dextrans with erythrocytes.
    Rampling M; Sirs JA
    J Physiol; 1972 May; 223(1):199-212. PubMed ID: 5046146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibrinogen and platelet aggregation. Role of the glycopeptidic part and of the fibrinopeptide B. Description of a new technique of fibrinoglycopeptide isolation.
    Soria J; Soria C; Bertrand O; Samama M
    Biochem Biophys Res Commun; 1978 May; 82(2):442-50. PubMed ID: 666853
    [No Abstract]   [Full Text] [Related]  

  • 23. [Fluctuation of plasma levels of fibrinogen degradation products, fibrin degradation products and total fibrin/fibrinogen degradation products in patients with DIC].
    Isogai N; Kuroso K; Fujimaki M; Yorifuji H; Fukutake K
    Rinsho Byori; 1993 Dec; 41(12):1349-52. PubMed ID: 8295346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Correlation of fragmented cells with lytic products and other hematologic data].
    Rodríguez-Cerrillo Ríos GA; Lepe Zúñiga JL
    Bol Med Hosp Infant Mex; 1981; 38(2):243-9. PubMed ID: 7259845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrin (ogen) degradation products and prostaglandin interactions on human basilar artery [proceedings].
    Forster C; Mohan J; Whalley ET
    Br J Clin Pharmacol; 1980 Mar; 9(3):219P. PubMed ID: 7362729
    [No Abstract]   [Full Text] [Related]  

  • 26. Dose-dependent nature of the interaction of fibrinogen-degradation products and 5-hydroxytryptamine on various vascular smooth muscle preparations [proceedings].
    Forster C; Mohan J; Whalley ET
    Br J Pharmacol; 1980 Jan; 68(1):151P. PubMed ID: 7357163
    [No Abstract]   [Full Text] [Related]  

  • 27. [Determination of blood fibrinogen (fibrin) degradation products by reaction to hemagglutination delay of sensitized erythrocytes].
    Ponizovskiĭ MP; Tsynkalovskaia SN
    Vrach Delo; 1976 Aug; (8):115-7. PubMed ID: 1020269
    [No Abstract]   [Full Text] [Related]  

  • 28. [Anticlotting activity of fragment D from fibrinogen and fibrin and its dependence on calcium presence when fragments are obtained from fibrinogen].
    Tolstikh VM; Varets'ka TV
    Ukr Biokhim Zh; 1976; 48(1):116-21. PubMed ID: 1258156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The COOH-terminal globular domain of fibrinogen gamma chain suppresses angiogenesis and tumor growth.
    Akakura N; Hoogland C; Takada YK; Saegusa J; Ye X; Liu FT; Cheung AT; Takada Y
    Cancer Res; 2006 Oct; 66(19):9691-7. PubMed ID: 17018627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fragment E derived from both fibrin and fibrinogen stimulates interleukin-6 production in rat peritoneal macrophages.
    Lee ME; Rhee KJ; Nham SU
    Mol Cells; 1999 Feb; 9(1):7-13. PubMed ID: 10102564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The antifibrinolytic action of the D-dimer fragment].
    Rozenfel'd MA; Khavkina LS; Leonova VB; Gershkovich KB; Vasil'eva MV
    Izv Akad Nauk SSSR Biol; 1989; (6):855-61. PubMed ID: 2621282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrin-mediated vascular injury: demonstration of vascular endothelial cell retraction in response to soluble fibrin-associated factors.
    Rowland FN; Donovan MJ; Picciano PT; Kreutzer DL
    J Exp Pathol; 1984; 1(3):217-40. PubMed ID: 6599938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Monoclonal antibodies against fibrinogen and fibrin and against their proteolytic degradation products].
    Dyr JE; Cajthamlová H; Suttnar J
    Cas Lek Cesk; 1990 Oct; 129(43):1349-51. PubMed ID: 2249231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The binding of fibrinogen and fibrinogen degradation products to the erythrocyte membrane and its relationship to haemorheology.
    Rampling MW
    Acta Biol Med Ger; 1981; 40(4-5):373-8. PubMed ID: 7315086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibrinogen E-fragment inhibits the migration and tubule formation of human dermal microvascular endothelial cells in vitro.
    Bootle-Wilbraham CA; Tazzyman S; Marshall JM; Lewis CE
    Cancer Res; 2000 Sep; 60(17):4719-24. PubMed ID: 10987275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of albumin degradation products (ADP) on the action of acetylcholine in the central nervous system.
    Buczko W; Józefów D; Ostaszewska-Puchajda B
    Acta Med Pol; 1979; 20(3):173-9. PubMed ID: 517158
    [No Abstract]   [Full Text] [Related]  

  • 37. Fibrinogen degradation product-D, fibrinogen, and serum change polymorphonuclear granulocyte activity--possibly important post-trauma?
    Vogel P; Klosterhalfen B; Kirkpatrick CJ; Schöne S
    J Trauma; 1991 Jan; 31(1):87-92. PubMed ID: 1846014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory effect of D and DD fragments on fibrin polymerization.
    Loukinova NI; Platonova TN
    Ukr Biokhim Zh (1978); 1996; 68(4):17. PubMed ID: 9226804
    [No Abstract]   [Full Text] [Related]  

  • 39. Observations on some factors affecting the flexibility of erythrocyte membranes.
    Rampling MW; Sirs JA
    Acta Biol Med Ger; 1977; 36(5-6):845-6. PubMed ID: 414495
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of plasmin on erythrocyte sedimentation rate.
    Fukutake K; Suzuki H; Mikami T; Hanazawa K; Kano T
    Nihon Ketsueki Gakkai Zasshi; 1968 Apr; 31(2):Suppl:11-23. PubMed ID: 5752621
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.